In the beginning of 2010, clinical studies targeting leukemia and lymphoma accounted for the majority of studies, but in recent years, studies targeting multiple myeloma (MM) and solid tumors have been increasing, and the indications for CAR-T have been expanding based on the success of CD19-targeted CAR-T-cell therapy. Here, CD19 is linked to lymphoma.